These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32507446)

  • 21. A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease.
    Zhang PW; Chen FX; Li D; Ling WH; Guo HH
    Medicine (Baltimore); 2015 May; 94(20):e758. PubMed ID: 25997043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study.
    Panahi Y; Kianpour P; Mohtashami R; Soflaei SS; Sahebkar A
    J Asian Nat Prod Res; 2019 Aug; 21(8):798-805. PubMed ID: 30415581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
    Panahi Y; Kianpour P; Mohtashami R; Jafari R; Simental-Mendía LE; Sahebkar A
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):223-9. PubMed ID: 27124606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
    Gheibi S; Gouvarchin Ghaleh HE; Motlagh BM; Azarbayjani AF; Zarei L
    Biomed Pharmacother; 2019 Jul; 115():108938. PubMed ID: 31071511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
    Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial.
    Korovljev D; Stajer V; Ostojic J; LeBaron TW; Ostojic SM
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):688-693. PubMed ID: 30982748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial.
    Amanat S; Eftekhari MH; Fararouei M; Bagheri Lankarani K; Massoumi SJ
    Clin Nutr; 2018 Aug; 37(4):1210-1215. PubMed ID: 28647291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial.
    Panahi Y; Kianpour P; Mohtashami R; Atkin SL; Butler AE; Jafari R; Badeli R; Sahebkar A
    Phytother Res; 2018 Jul; 32(7):1382-1387. PubMed ID: 29520889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features.
    Rahmanabadi A; Mahboob S; Amirkhizi F; Hosseinpour-Arjmand S; Ebrahimi-Mameghani M
    Food Funct; 2019 Aug; 10(8):4941-4952. PubMed ID: 31343010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
    Anushiravani A; Haddadi N; Pourfarmanbar M; Mohammadkarimi V
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):613-617. PubMed ID: 30920975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.
    Lorvand Amiri H; Agah S; Mousavi SN; Hosseini AF; Shidfar F
    Arch Iran Med; 2016 Sep; 19(9):631-8. PubMed ID: 27631178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of ADIPOQ methylation in curcumin-administrated experimental nonalcoholic fatty liver disease.
    Chen WJ; Cai B; Chen HT; Cao CY; Du YL; Li YY; Nie YQ; Zhou YJ
    J Dig Dis; 2016 Dec; 17(12):829-836. PubMed ID: 27860427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.
    Dabbaghmanesh MH; Danafar F; Eshraghian A; Omrani GR
    Diabetes Metab Syndr; 2018 Jul; 12(4):513-517. PubMed ID: 29588137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Wei Z; Liu N; Tantai X; Xing X; Xiao C; Chen L; Wang J
    Hepatol Int; 2019 May; 13(3):302-313. PubMed ID: 30446932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.